-
-
-
-
-
-
-
Unicycive Therapeutics (UNCY) PT Lowered to $63 at Lucid Capital Markets
-
-
-
-
-
-
-
Benchmark Reiterates Speculative Buy Rating on Unicycive Therapeutics (UNCY)
-
-
-
-
-
-
-
Unicycive to Highlight Patient Reported Outcomes Data at Upcoming Medical Meetings Showing Oxylanthanum Carbonate Reduced Pill Burden and Improved Adherence in Treatment of Hyperphosphatemia
-
-
-
-
-
-
-
Unicycive Therapeutics Announces Publication of Oxylanthanum Carbonate (OLC) Positive Bioequivalence Data in Clinical Therapeutics
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Unicycive Therapeutics (UNCY)
-
-
14,982 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

